Comparable Benefits of HCV Eradication by Direct Acting Antivirals and Interferon-based Therapy in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 Dec 7

PMID 34873477

Citations 1

Authors

Kuo-Cheng Wu

I-Cheng Lee

Chen-Ta Chi

Hao-Jan Lei

Gar-Yang Chau

Yi-Chen Yeh

Chien-Wei Su

Teh-Ia Huo

Yee Chao

Han-Chieh Lin

Ming-Chih Hou

Yi-Hsiang Huang

Affiliations

Soon will be listed here.

Abstract

Whether direct-acting antivirals (DAA) provide comparable survival benefit with interferon (IFN)-based therapy remains unclear. The aim of this study was to compare the outcomes after achieving SVR by IFN-based and DAA therapy after resection of HCV-related hepatocellular carcinoma (HCC). Consecutive 285 patients receiving curative resection for HCV-related HCC were retrospectively enrolled, including 103 (36.1%) and 69 (24.2%) patients with IFN-based and DAA therapy, respectively. Factors associated with recurrence, overall survival (OS) and hepatic decompensation-free survival were evaluated. The SVR rate of DAA was 95.7% in HCC patients. During a median follow-up period of 49.6 months, 102 (35.8%) patients died and 63 (24%) developed hepatic decompensation. By multivariate analysis, SVR by DAA or IFN-based therapy was not associated with early or late HCC recurrence. Achieving SVR (by IFN-based therapy: HR=0.321, P<0.001; by DAA: HR=0.396, P=0.011), BCLC stage B-C (HR=1.914, P=0.024), FIB-4 score >3.25 (HR=1.664, P=0.016) and microvascular invasion (HR=1.603, P=0.048) were independent predictors of OS. Achieving SVR (by IFN-based therapy: HR=0.295, P<0.001; by DAA: HR=0.193, P=0.002), BCLC stage B-C (HR=2.975, P=0.001), GGT >70 U/L (HR=1.931, P=0.015) and cirrhosis (HR=2.035, P=0.007) were independent predictors of decompensation-free survival. The benefit of achieving SVR was consistently observed in cirrhotic and non-cirrhotic patients, and in patients with and without HCC recurrence. In conclusion, achieving SVR by either DAA or IFN-based therapy provide comparable and significant reduction of mortality and hepatic decompensation after surgical resection of HCV-related HCC. DAA therapy should be prescribed for all HCC patients after curative surgical resection.

Citing Articles

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib.

Kuo Y, Huang T, Wang J, Chen Y, Tsai M, Chen Y Cancers (Basel). 2022; 14(16).

PMID: 36010961 PMC: 9406667. DOI: 10.3390/cancers14163971.

References

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Beste L, Green P, Berry K, Kogut M, Allison S, Ioannou G . Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017; 67(1):32-39. PMC: 6590903. DOI: 10.1016/j.jhep.2017.02.027. View

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Singal A, Rich N, Mehta N, Branch A, Pillai A, Hoteit M . Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019; 157(5):1253-1263.e2. PMC: 6815711. DOI: 10.1053/j.gastro.2019.07.040. View

Huang C, Yeh M, Tsai P, Hsieh M, Yang H, Hsieh M . Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014; 61(1):67-74. DOI: 10.1016/j.jhep.2014.02.022. View

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D . Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. J Hepatol. 2020; 73(6):1434-1445. DOI: 10.1016/j.jhep.2020.05.052. View

Wu J, Huang Y, Chau G, Su C, Lai C, Lee P . Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009; 51(5):890-7. DOI: 10.1016/j.jhep.2009.07.009. View

Manthravadi S, Paleti S, Pandya P . Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer. 2016; 140(5):1042-1049. DOI: 10.1002/ijc.30521. View

10.

Everhart J, Wright E . Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology. 2012; 57(5):1725-33. PMC: 3624035. DOI: 10.1002/hep.26203. View

11.

Lee I, Huang Y, Chau G, Huo T, Su C, Wu J . Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. 2013; 133(12):2895-902. DOI: 10.1002/ijc.28311. View

12.

Lee M, Yang H, Lu S, Jen C, Yeh S, Liu C . Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010; 28(30):4587-93. DOI: 10.1200/JCO.2010.29.1500. View

13.

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003; 138(4):299-306. DOI: 10.7326/0003-4819-138-4-200302180-00008. View

14.

Saraiya N, Yopp A, Rich N, Odewole M, Parikh N, Singal A . Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018; 48(2):127-137. PMC: 6019180. DOI: 10.1111/apt.14823. View

15.

Falade-Nwulia O, Suarez-Cuervo C, Nelson D, Fried M, Segal J, Sulkowski M . Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017; 166(9):637-648. PMC: 5486987. DOI: 10.7326/M16-2575. View

16.

Lee I, Chau G, Yeh Y, Chao Y, Huo T, Su C . Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One. 2017; 12(11):e0188552. PMC: 5703552. DOI: 10.1371/journal.pone.0188552. View

17.

Hsu C, Chao Y, Lin H, Chen D, Kao J . Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep. 2015; 5:9954. PMC: 4428066. DOI: 10.1038/srep09954. View

18.

Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F . Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017; 67(1):65-71. DOI: 10.1016/j.jhep.2017.01.033. View

19.

Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G . Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer. 2018; 7(3):261-276. PMC: 6170901. DOI: 10.1159/000486902. View

20.

Backus L, Belperio P, Shahoumian T, Mole L . Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018; 68(3):827-838. DOI: 10.1002/hep.29811. View